Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women

Diabetologia

Volumn 52, Issue 1, 2009, Pages 160-168

  Yu, Y ^a   Jenkins, A J ^a,b   Nankervis, A J ^c   Hanssen, K F ^d,e,f   Scholz, H ^g   Henriksen, T ^g   Lorentzen, B ^g   Clausen, T ^d   Garg, S K ^h   Menard, M K ⁱ   Hammad, S M ^j   Scardo, J C ^k   Stanley, J R ^l   Dashti, A ^a   May, K ^a   Lu, K ^a   Aston, C E ^a   Wang, J J ^a   Zhang, S X ^a   Ma, J X ^a   Lyons, T J ^a   more..

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e AKER UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF COLORADO DENVER   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^k Gibbs Cancer Center and Research Institute   (United States)

^l Mercy Health Center   (United States)

more..

Author keywords

Anti angiogenic factors; Diabetes; Endoglin; Pigment epithelium derived factor; Placental growth factor; Pre eclampsia; Pregnancy; SFlt1; Soluble VEGF receptors

Indexed keywords

ALBUMIN; CREATININE; ENDOGLIN; HEMOGLOBIN A1C; PIGMENT EPITHELIUM DERIVED FACTOR; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE PREDISPOSITION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MICROALBUMINURIA; MULTICENTER STUDY; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; THIRD TRIMESTER PREGNANCY;

EID: 57249094203     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-008-1182-x     Document Type: Article

References (27)

1. JM Roberts G Pearson J Cutler M Lindheimer 2003 Summary of the NHLBI working group on research on hypertension during pregnancy Hypertension 41 437 445
2. U Hanson B Persson 1993 Outcome of pregnancies complicated by type 1 insulin-dependent diabetes in Sweden: acute pregnancy complications, neonatal mortality and morbidity Am J Perinatol 10 330 333
3. CD Hsu HY Tan SF Hong NA Nickless JA Copel 1996 Strategies for reducing the frequency of preeclampsia in pregnancies with insulin-dependent diabetes mellitus Am J Perinatol 13 65 68
4. L Zhu M Nakabayashi Y Takeda 1997 Statistical analysis of perinatal outcomes in pregnancy complicated with diabetes mellitus J Obstet Gynaecol Res 23 555 563
5. IM Evers HW de Valk GH Visser 2004 Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands BMJ 328 915
6. RJ Levine SE Maynard C Qian 2004 Circulating angiogenic factors and the risk of preeclampsia N Engl J Med 350 672 683
7. RJ Levine C Lam C Qian 2006 Soluble endoglin and other circulating antiangiogenic factors in preeclampsia N Engl J Med 355 992 1005
8. S Rana SA Karumanchi RJ Levine 2007 Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia Hypertension 50 137 142
9. H Stepan A Geide R Faber 2004 Soluble fms-like tyrosine kinase 1 N Engl J Med 351 2241 2242
10. S Venkatesha M Toporsian C Lam 2006 Soluble endoglin contributes to the pathogenesis of preeclampsia Nat Med 12 642 649
11. SE Maynard JY Min J Merchan 2003 Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest 111 649 658
12. R Romero JK Nien J Espinoza 2008 A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate J Matern Fetal Neonatal Med 21 9 23
13. SX Zhang JJ Wang G Gao C Shao R Mott JX Ma 2006 Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor FASEB J 20 323 325
14. JJ Wang SX Zhang K Lu 2005 Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy Diabetes 54 243 250
15. NH Kim JH Oh JA Seo 2005 Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy Kidney Int 67 167 177
16. A Blann FM Belgore CN McCollum S Silverman PL Lip GY Lip 2002 Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes Cli Sci 102 187 194
17. A Martin MR Komada DC Sane 2003 Abnormal angiogenesis in diabetes mellitus Med Res Rev 23 117 145
18. S Yamagishi H Adachi A Abe 2006 Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome J Clin Endocrinol Metab 91 2447 2450
19. AJ Jenkins SX Zhang KG Rowley 2007 Increased serum pigment epithelium derived factor is associated with microvascular complications, vascular stiffness, and inflammation in type 1 diabetes Diabet Med 24 1345 1351
20. N Ogata M Matsuoka K Matsuyama 2007 Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy J Clin Endocrinol Metab 92 1176 1179
21. R Mittendorf KY Lain MA Williams CK Walker 1996 Preeclampsia: a nested, case-control study of risk factors and their interactions J Reprod Med 41 491 496
22. F Parazzini R Bortolus L Chatenoud 1996 Risk factors for pregnancy-induced hypertension in women at high risk for the condition. Italian Study of Aspirin in Pregnancy Group Epidemiology 7 306 308
23. S Caritis B Sibai J Hauth 1998 Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units Am J Obstet Gynecol 179 946 951
24. No authors listed (2000) National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. National Heart, Lung and Blood Institute, Bethesda, MD. National Institutes of Health publication 00-3029:1-38
25. M Wolf A Shah C Lam 2005 Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies Am J Obstet Gynecol 193 16 22
26. J Zhang MA Klebanoff RJ Levine M Puri P Moyer 1999 The puzzling association between smoking and hypertension during pregnancy Am J Obstet Gynecol 181 1407 1413
27. FM Belgore GY Lip AD Blann 2000 Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers Br J Biomed Sci 57 207 213